9 completed, 6 recruiting, 3 terminated, 3 unknown. 19 Phase 1, 8 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 19 | Completed 8, Recruiting 5, Terminated 3, Unknown 3 |
| Phase 2 | 8 | Completed 2, Recruiting 2, Unknown 2, Active not recruiting 1, Terminated 1 |
Follow Advanced Tumors: new trials by email Literature Review of Advanced Tumors trials Research Report on Advanced Tumors
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase I Trial of GW01-200 Tablets in Subjects With Advanced Tumors GW01-200 - Advanced Tumors | Phase 1 | Recruiting | Groovy Medicine (Hangzhou) Ltd. | 100 | 2026-07-17 | 2026-08-14 |
| A Clinical Trial of SIBP-A10 Injection in the Treatment of Advanced Malignant Tumor Subjects. SIBP-A10 - Advanced Tumors | Phase 1 | Recruiting | Shanghai Institute Of Biological Products | 160 | 2025-10-31 | 2026-01-08 |
| Dose Escalation and Dose Expansion Study of MDX2004 in Participants With Advanced Tumors MDX2004 - Advanced Tumors | Phase 1 / Phase 2 | Recruiting | ModeX Therapeutics, An OPKO Health Company | 235 | 2025-10-01 | 2026-03-05 |
| Tarlatamab in Advanced Delta-like 3 (DLL3)-Expressing Tumors Including Neuroendocrine Neoplasms Tarlatamab treatment - DLL3-expressing Tumors, Advanced Tumors | Phase 2 | Active not recruiting | Jonsson Comprehensive Cancer Center | 29 | 2025-03-21 | 2026-09-01 |
| A Study of CS23546 in Subjects With Advanced Tumors CS23546 - Advanced Tumors | Phase 1 | Recruiting | Chipscreen Biosciences, Ltd. | 156 | 2024-03-27 | 2026-04-06 |
| Individualized Neoantigen Therapy with Unusual Radiotherapy Enhancement (iNATURE) Placebo + conventional treatment including radiotherapy, Radiation: Radiation Therapy；Biological: Personalized tumor peptide vaccine - Advanced Tumors | Phase 2 | Recruiting | The University of Hong Kong-Shenzhen Hospital | 154 | 2024-01-31 | 2025-03-25 |
| A SHR-1210 BE Study on Healthy Subjects SHR-1210 - Advanced Tumors | Phase 1 | Terminated | Jiangsu HengRui Medicine Co., Ltd. | 12 | 2023-07-04 | 2024-12-31 |
| A Phase I Clinical Study of HMPL-A83 in Patients With Advanced Malignant Neoplasm HMPL-A83 injection - Advanced Tumors | Phase 1 | Completed | Hutchmed | 40 | 2022-07-15 | 2025-06-18 |
| A Study Evaluating the Safety, Tolerability, Pharmacokinetic and Efficacy of HLX301(TIGIT×PDL1 Bispecific) in Locally Advanced/Metastatic Solid Tumors or Lymphoma HLX301 - Advanced Tumors, Lymphoma | Phase 1 / Phase 2 | Unknown | Shanghai Henlius Biotech | 30 | 2022-06-20 | 2023-08-08 |
| A Study of PM1022 in Patients With Advanced Tumors PM1022 - Advanced Tumors | Phase 1 / Phase 2 | Unknown | Biotheus Inc. | 200 | 2022-04-11 | 2023-05-22 |
| Clinical Study to Evaluate the Tolerability and Pharmacokinetics of TQB2916 Injection in Patients With Advanced Malignant Tumors TQB2916 injection - Advanced Tumors | Phase 1 | Unknown | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | 190 | 2022-02-01 | 2022-01-28 |
| A Study of HRS2543 in Patients With Advanced Tumors HRS2543 - Advanced Tumors | Phase 1 | Terminated | Shanghai Hengrui Pharmaceutical Co., Ltd. | 10 | 2021-12-28 | 2024-07-18 |
| Phase I Study of CPI-300 in Patients With Advanced Tumors CPI-300 - Advanced Tumors | Phase 1 | Completed | Coordination Pharmaceuticals, Inc. | 17 | 2021-06-15 | 2024-02-07 |
| The Recombinant Humanized Anti-TIGIT Monoclonal Antibody (JS006) Monotherapy and in Combination With Toripalimab in Patients With Advanced Tumor JS006 as Monotherapy, JS006 in combination with Toripalimab - Advanced Tumors | Phase 1 | Completed | Shanghai Junshi Bioscience Co., Ltd. | 47 | 2021-04-21 | 2026-07-09 |
| A Study of AL58805 in Patients With Advanced Tumors AL58805 - Advanced Tumors | Phase 1 | Recruiting | Advenchen Laboratories Nanjing Ltd. | 40 | 2020-12-20 | 2025-09-17 |
| A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced Tumors HH2710 - Advanced Tumors, Melanoma | Phase 1 / Phase 2 | Terminated | Haihe Biopharma Co., Ltd. | 37 | 2020-01-07 | 2024-07-19 |
| Phase I Clinical Trial of CDP1 in Patients With Advanced Solid Tumors CDP1, TIP chemotherapy - Advanced Tumors | Phase 1 | Completed | Dragonboat Biopharmaceutical Company Limited | 32 | 2019-12-16 | 2024-08-27 |
| Phase I Clinical Trial of Human Anti-PD-L1 Antibody Injection (LDP) in Patients With Advanced Malignant Tumors Whole Human Anti-PD-L1 Antibody Injection (LDP) - Advanced Tumors | Phase 1 | Completed | Dragonboat Biopharmaceutical Company Limited | 66 | 2019-04-27 | 2026-07-06 |
| Platform Trial Evaluating Safety and Efficacy of Ezabenlimab Anti- PD-1 Based Combination Therapies in PD-(L)1 naïve and PD- (L)1 Pretreated Patient Populations With Advanced/Metastatic Solid Tumours Ezabenlimab, BI 754111, BI 836880 - Neoplasm Metastasis, Advanced Tumors | Phase 2 | Completed | Boehringer Ingelheim | 211 | 2019-03-19 | 2026-01-27 |
| Study of CPI-100 in Patients With Advanced Tumors CPI-100, Capecitabine - Advanced Tumors | Phase 1 | Completed | Coordination Pharmaceuticals, Inc. | 36 | 2018-12-21 | 2022-07-20 |
Showing 20 of 22. Sign in to see all of them.
Neoplasm Metastasis (2) · Carcinoma, Non-Small-Cell Lung (1) · Erdheim-Chester Disease (1) · Lymphoma (1) · Melanoma (1) · Neoplasms (1)
Neoplasms (3) · Hemic and Lymphatic Diseases (2) · Lymphatic Diseases (2) · Neoplasms by Histologic Type (2) · Neoplastic Processes (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Bronchial Neoplasms (1) · Carcinoma, Bronchogenic (1) · Histiocytosis (1) · Histiocytosis, Non-Langerhans-Cell (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Lung Diseases (1) · Lung Neoplasms (1)
Capecitabine (1) · Nivolumab (1) · Radiotherapy (1) · camrelizumab (1) · toripalimab (1)
Coordination Pharmaceuticals, Inc. (3) · Dragonboat Biopharmaceutical Company Limited (2) · Advenchen Laboratories Nanjing Ltd. (1) · Biotheus Inc. (1) · Boehringer Ingelheim (1) · Bristol-Myers Squibb (1) · Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. (1) · Chipscreen Biosciences, Ltd. (1) · Groovy Medicine (Hangzhou) Ltd. (1) · Haihe Biopharma Co., Ltd. (1) · Hutchmed (1) · Jiangsu HengRui Medicine Co., Ltd. (1) · Jonsson Comprehensive Cancer Center (1) · ModeX Therapeutics, An OPKO Health Company (1) · Shanghai Hengrui Pharmaceutical Co., Ltd. (1)
China (15) · United States (7) · Australia (2) · Canada (2) · France (1) · Israel (1) · Spain (1) · United Kingdom (1)
Ye Guo (2) · Dongfang Li (1) · Huiqiang Huang, Ph.D. (1) · Jonathan Goldman, MD (1) · Li Jin, doctor (1) · Li Zhang, Docter (1) · Li Zheng, doctor (1) · Yongchang Zhang (1)
2015 (1), 2018 (1)